Understanding how FAK affects cancer growth in ovarian cancer
Dissecting FAK-regulated oncogenic signaling programs in ovarian cancer
This study is looking at how a protein called FAK affects the growth and treatment resistance of high-grade serous ovarian cancer, using a special mouse model to help find new ways to improve treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10830960 on NIH RePORTER |
What this research studies
This research investigates the role of focal adhesion kinase (FAK) in the development and resistance of high-grade serous ovarian cancer (HGSOC). By using a new mouse model that mimics the genetic complexity of HGSOC, the researchers aim to uncover how FAK signaling contributes to the cancer's ability to resist chemotherapy. The study employs various techniques, including genetic manipulation and bioinformatics, to analyze how FAK influences cancer cell behavior and survival. Patients may benefit from insights gained about FAK's role in treatment resistance, potentially leading to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, especially those experiencing treatment resistance.
Not a fit: Patients with other types of ovarian cancer or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, particularly for patients who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown that targeting FAK in cancer models can lead to promising results, indicating that this approach may be effective.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Schlaepfer, David D — University of California, San Diego
- Study coordinator: Schlaepfer, David D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.